Jagsonpal Pharmaceuticals

NSE: JAGSNPHARM · Pharmaceuticals · sector

₹223.06NSE close 2026-10-26

Key numbers

Market cap₹1,469 cr

Price₹223.06

52w high / low₹264 / ₹155

P/E32.8xSector median 27.9x

P/B5.3xSector median 2.9x

Book value₹42.0

Dividend yield–Sector median 0.48%

ROE17.6%Sector median 11.7%

ROCE22.4%Sector median 12.3%

OPM20.1%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA23.1xSector median 18.6x

Interest cover60.3x

Current ratio5.06x

Sales growth 3y+6.7%Sector median +9.6%

Profit growth 3y+17.3%Sector median +13.3%

PEG2.03x

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹106 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Operating profit covered interest 60.3x in the last 12 months.
No promoter shares are pledged.
Promoter holding rose by 1.27 percentage points in a year, to 68.81% (2026-09-30).
Operating cash flow was below net profit in 2 of the last 5 years (FY25, FY22).
Revenue was higher than a year earlier in 2 of the last 4 quarters.
Other income was 26% of net profit in the last 12 months.
Dividend paid in 4 of the last 5 financial years.
Price ₹223.06 on 2026-10-26: -15.7% from the 52-week high, +43.9% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹289.12 · low ₹165.27

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	75	74	59	76	74	73	64	82
EBITDA	16	39	8	14	16	14	11	17
OPM %	21.8%	52.7%	14.5%	18.8%	22.1%	19.5%	17.4%	21.0%
Other income	2	2	3	3	3	3	3	3
Net profit	11	32	7	11	13	11	9	13
EPS (₹)	1.72	1.90	0.98	1.60	1.88	1.67	1.25	2.00
Revenue YoY					-0.3%	-1.5%	+9.6%	+8.8%
Profit YoY					+9.7%	-65.8%	+33.1%	+22.2%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	226	237	209	269	287	294
EBITDA	26	31	23	71	56	59
Net profit	20	27	22	55	43	45
EPS (₹)	2.99	4.08	3.40	8.26	6.40	6.80
Revenue growth		+4.7%	-11.8%	+28.8%	+6.9%	+3.9%
Profit growth		+36.4%	-15.9%	+146.5%	-22.2%	-25.2%
Dividend / share (₹)	5.00	–	5.00	5.00	2.50

Compounded growth	3 years	5 years	Last 12 months
Sales	+6.7%	+8.9%	+3.9%
Net profit	+17.3%	+20.4%	-25.2%
EPS	+16.2%	+19.7%	–
Share price	–	+5.7% (2y)	-1.6%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	159	187	240	276
Borrowings	–	0	0	0	0
Cash & equivalents	–	115	148	129	106
Total assets	–	195	217	278	317
Fixed assets	–	18	1	1	1
Capital work in progress	–	0	0	0	0
Investments	–	1	0	0	0
Receivables	–	21	11	13	17
Inventory	–	21	15	15	15
Payables	–	16	8	10	12

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	6	40	35	55	47
Cash from investing	-26	-52	-25	-45	-36
Cash from financing	-12	0	-9	-12	-12
Capex	0	0	0	0	0
Free cash flow	5	40	35	55	47

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	16.8%	12.0%	23.1%	15.6%
ROCE %	–	22.2%	16.4%	29.5%	21.2%
Debtor days	–	32	19	18	22
Inventory days	–	81	68	58	51
Payable days	–	64	35	37	40
Cash conversion cycle (days)	–	49	52	39	33
Working capital days	–	211	315	184	146

Shareholding

Holder	% (2026-09-30)
Promoters	68.81%
FIIs	2.14%
DIIs	1.65%
of which Mutual funds	0.00%
Public (non-institutions)	27.40%

Quarter	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jun 2026	Sep 2026
Promoters %	67.78%	67.65%	67.54%	67.39%	67.89%	69.36%	69.05%	68.81%

Promoter group	%
Aresko Progressive Private Limited (Trustee of Aresko Progressive Trust, in the capacity of representative) partner of J&P Investments Partnership)	20.19%
INFINITY CAPITAL (Formerly Infinity Holdings Sidecar1)	18.00%
Infinity Holdings	16.70%
Infinity Portfolio Holdings	8.66%
Rajpal Singh Kochhar	4.59%
Prithipal Singh Kochhar	0.41%
Inderpal Singh Kochhar	0.28%
Ishpinder Kaur Kochhar	0.00%
Rakshit Organisational Operations and Transformations Pvt. Ltd.	0.00%
Aresko Life Sciences Private Limited	0.00%
Aresko Restaurants Private Limited	0.00%
Aresko Services Limited	0.00%
Aresko Family Private Limited	0.00%
Aresko Realtors Private Limited	0.00%
Sewara Buildtech Private Limited	0.00%

Public holders above 1%	%
Manish Gupta	3.18%
Investor Education and Protection Fund Authority Ministry of Corporate Affairs	1.49%
Authum Investment and Infrastructure Limited	1.47%
Lincoln P Coelho	1.17%

26,537 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
JAGSNPHARM	₹1,469 cr	32.8x	5.3x	17.6%	22.4%	20.1%	+6.7%	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-09-04	Dividend	Dividend - Rs 4 Per Share
2026-05-04	Buyback	Buy Back
2025-09-12	Dividend	Dividend - Rs 2.50 Per Share
2025-01-08	Split	Face Value Split (Sub-Division) - From Rs 5/- Per Share To Rs 2/- Per Share
2024-09-06	Dividend	Dividend - Rs 5 Per Share
2023-08-21	Dividend	Dividend - Rs 5 Per Share
2022-06-08	Other	Extra Ordinary General Meeting
2021-10-29	Dividend	Interim Dividend - Rs 4 Per Share
2021-09-22	Dividend	Annual General Meeting/Dividend - Re 1 Per Share
2020-09-22	Dividend	Annual General Meeting/Dividend - Rs 0.50 Per Share
2019-09-20	Dividend	Annual General Meeting/Dividend - Rs 0.25 Per Share
2018-09-18	Dividend	Annual General Meeting/Dividend Re 0.10 Per Share
2017-09-21	Dividend	Annual General Meeting/Dividend - Re 0.10 Per Share (Date Revised)
2016-09-21	Dividend	Annual General Meeting/ Dividend - Re 0.10/- Per Share (Book Closure Start Date Revised)
2015-09-21	Dividend	Annual General Meeting/ Dividend - Re 0.10/- Per Share
2014-09-25	Dividend	Annual General Meeting / Dividend - Re 0.50/- Per Share
2013-09-25	Dividend	Annual General Meeting/Dividend Re 0.50/- Per Share
2012-09-21	Dividend	Annual General Meeting/Dividend Re 0.50 Per Share
2011-09-23	Dividend	Annual General Meeting And Dividend Re.0.50 Per Share
2010-09-21	Dividend	Annual General Meeting And Dividend Re.0.50 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Pharmaceuticals: The company is engaged in the business of marketing and distribution of pharmaceutical formulations


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	JAGSNPHARM
BSE code	507789
ISIN	INE048B01035
Face value	₹2.0
Incorporated	1978-08-17
Website	www.jagsonpal.com
Plants (India / abroad)	0 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.